Preliminary Report on the Effect of Ketamine in Patients with Central Pain

This preliminary open prospective study reports on the effect of ketamine, an N-methyl-D-aspartate (NMDA)-receptor noncompetitive antagonist, in five patients suffering from central poststroke pain (CPSP). Patients were evaluated at rest on a visual analogue scale (VAS) graded from 0 to 10. Pain mea...

Full description

Saved in:
Bibliographic Details
Main Authors: Sylvie Rostaing-Rigatti, Pierre Cesaro, Jean-Paul N’Guyen, Jean-François Ejzenbaum, Bernard Pollin, Francis Bonnet
Format: Article
Language:English
Published: Wiley 1997-01-01
Series:Pain Research and Management
Online Access:http://dx.doi.org/10.1155/1997/523784
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832567402379870208
author Sylvie Rostaing-Rigatti
Pierre Cesaro
Jean-Paul N’Guyen
Jean-François Ejzenbaum
Bernard Pollin
Francis Bonnet
author_facet Sylvie Rostaing-Rigatti
Pierre Cesaro
Jean-Paul N’Guyen
Jean-François Ejzenbaum
Bernard Pollin
Francis Bonnet
author_sort Sylvie Rostaing-Rigatti
collection DOAJ
description This preliminary open prospective study reports on the effect of ketamine, an N-methyl-D-aspartate (NMDA)-receptor noncompetitive antagonist, in five patients suffering from central poststroke pain (CPSP). Patients were evaluated at rest on a visual analogue scale (VAS) graded from 0 to 10. Pain measurement was repeated at 15 and 30 mins following intravenous administration of 0.15 to 0.25 mg/kg ketamine and then every 30 mins for 6 h. Pain evoked by light touch or cold stimulation was also measured in three patients at those times. Patients were monitored for arterial pressure, heart rate, sedation and side effects during the study. Ketamine provided a significant improvement in pain at rest and in evoked pain. A 51% to 84% decrease in the VAS score for pain at rest was observed within 60 to 180 mins. Satisfactory pain relief (more than 50% decrease in the VAS score) lasted for 150 to 210 mins. Two patients had a prolonged improvement over two or three days. Arterial pressure and heart rate did not change significantly. Mild or moderate sedation was noticed in all patients for 20 to 30 mins. These results suggest that blockade of NMDA receptors may provide pain relief in patients suffering from CPSP.
format Article
id doaj-art-c4a2864ae17b41f6a49ce55904fc0a4c
institution Kabale University
issn 1203-6765
language English
publishDate 1997-01-01
publisher Wiley
record_format Article
series Pain Research and Management
spelling doaj-art-c4a2864ae17b41f6a49ce55904fc0a4c2025-02-03T01:01:34ZengWileyPain Research and Management1203-67651997-01-01229510010.1155/1997/523784Preliminary Report on the Effect of Ketamine in Patients with Central PainSylvie Rostaing-Rigatti0Pierre Cesaro1Jean-Paul N’Guyen2Jean-François Ejzenbaum3Bernard Pollin4Francis Bonnet5Département d’Anesthésie-Réanimation, Service de Neurologie, Service de Neurochirurgie, Hôpital Henri Mondor, FranceINSERM U421, Faculté de Médecine, Cedex, FranceDépartement d’Anesthésie-Réanimation, Service de Neurologie, Service de Neurochirurgie, Hôpital Henri Mondor, FranceDépartement d’Anesthésie-Réanimation, Service de Neurologie, Service de Neurochirurgie, Hôpital Henri Mondor, FranceLaboratoire de physiologie de la Manducation, Université Paris VII, Paris, FranceDépartement d’Anesthésie-Réanimation, Service de Neurologie, Service de Neurochirurgie, Hôpital Henri Mondor, FranceThis preliminary open prospective study reports on the effect of ketamine, an N-methyl-D-aspartate (NMDA)-receptor noncompetitive antagonist, in five patients suffering from central poststroke pain (CPSP). Patients were evaluated at rest on a visual analogue scale (VAS) graded from 0 to 10. Pain measurement was repeated at 15 and 30 mins following intravenous administration of 0.15 to 0.25 mg/kg ketamine and then every 30 mins for 6 h. Pain evoked by light touch or cold stimulation was also measured in three patients at those times. Patients were monitored for arterial pressure, heart rate, sedation and side effects during the study. Ketamine provided a significant improvement in pain at rest and in evoked pain. A 51% to 84% decrease in the VAS score for pain at rest was observed within 60 to 180 mins. Satisfactory pain relief (more than 50% decrease in the VAS score) lasted for 150 to 210 mins. Two patients had a prolonged improvement over two or three days. Arterial pressure and heart rate did not change significantly. Mild or moderate sedation was noticed in all patients for 20 to 30 mins. These results suggest that blockade of NMDA receptors may provide pain relief in patients suffering from CPSP.http://dx.doi.org/10.1155/1997/523784
spellingShingle Sylvie Rostaing-Rigatti
Pierre Cesaro
Jean-Paul N’Guyen
Jean-François Ejzenbaum
Bernard Pollin
Francis Bonnet
Preliminary Report on the Effect of Ketamine in Patients with Central Pain
Pain Research and Management
title Preliminary Report on the Effect of Ketamine in Patients with Central Pain
title_full Preliminary Report on the Effect of Ketamine in Patients with Central Pain
title_fullStr Preliminary Report on the Effect of Ketamine in Patients with Central Pain
title_full_unstemmed Preliminary Report on the Effect of Ketamine in Patients with Central Pain
title_short Preliminary Report on the Effect of Ketamine in Patients with Central Pain
title_sort preliminary report on the effect of ketamine in patients with central pain
url http://dx.doi.org/10.1155/1997/523784
work_keys_str_mv AT sylvierostaingrigatti preliminaryreportontheeffectofketamineinpatientswithcentralpain
AT pierrecesaro preliminaryreportontheeffectofketamineinpatientswithcentralpain
AT jeanpaulnguyen preliminaryreportontheeffectofketamineinpatientswithcentralpain
AT jeanfrancoisejzenbaum preliminaryreportontheeffectofketamineinpatientswithcentralpain
AT bernardpollin preliminaryreportontheeffectofketamineinpatientswithcentralpain
AT francisbonnet preliminaryreportontheeffectofketamineinpatientswithcentralpain